<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634787</url>
  </required_header>
  <id_info>
    <org_study_id>158200-17-941-455</org_study_id>
    <nct_id>NCT03634787</nct_id>
  </id_info>
  <brief_title>Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis</brief_title>
  <acronym>DIAGNON</acronym>
  <official_title>Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of Heat Shock Proteins in the mechanism of acute severe pancreatitis.
      In addition to test the potential treatment target of acute pancreatitis.

      All patients who present with clinical symptoms of acute pancreatitis are evaluated for the
      enrollment of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients with acute pancreatitis are evaluated according to modified Atlanta
      classification acute pancreatitis severity scores.

      Blood serum, urine and DNA samples are collected from all patients presented on admission,
      after 24 hours, 48 hours, 72 hours.

      CT is performed in al patients to evaluate necrosis of pancreas Day 5-7 since hospital
      admission. If necrosis is not present follow-up is stopped.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the levels of heat shock proteins in serum and plasma in acute severe pancreatitis settings</measure>
    <time_frame>2 years</time_frame>
    <description>Different molecular weight Heat Shock proteins role while developing acute pancreatitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure pancreas cells activity while applying Heat Shock Protein inhibitors</measure>
    <time_frame>2 years</time_frame>
    <description>To establish a mechanism explaining the potential use of heat shock proteins inhibitors/ activators for treatment of acute pancreatitis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Acute pancreatitis</arm_group_label>
    <description>First time acute pancreatitis. No later than 2 days since the clinical symptoms started.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>No major systemic illness</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT Scan Day 5-7</intervention_name>
    <description>Computed Tomography on Day 5-7 according to a clinical protocol.</description>
    <arm_group_label>Acute pancreatitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples on admission
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to the hospital within 48 hours since the typical symptoms of acute
        pancreatitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no prior diagnosis of acute pancreatitis

          -  admission to the hospital within 2 days since the clinical symptoms

          -  confirmed diagnosis of acute pancreatitis

        Exclusion Criteria:

          -  chronic pancreatitis

          -  pancreatic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Kestutis Strupas, Prof. MD/PhD</last_name>
    <phone>+37052365000</phone>
    <email>kestutis.strupas@santa.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aiste Gulla, MD</last_name>
    <phone>+37052365000</phone>
    <email>aiste.kielaite-gulla@santa.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vilnius University Hospital &quot;Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08410</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kestutis Strupas, Prof.MD/PhD</last_name>
      <phone>+3705236500</phone>
      <email>kestutis.strupas@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Aiste Gulla, MD</last_name>
      <phone>+37052365000</phone>
      <email>aiste.kielaite-gulla@santa.lt</email>
    </contact_backup>
    <investigator>
      <last_name>Kestutis Strupas, Prof. MD/phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aiste Gulla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Aiste Gulla</investigator_full_name>
    <investigator_title>Senior surgery resident</investigator_title>
  </responsible_party>
  <keyword>Heat Shock Proteins, early diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We plan to share the data and recruitment status when the study reaches its requirement sample size</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

